Regeneron says antibody cocktail reduces risk of contracting Covid by 80% for at least 8 MONTHS  

BREAKING NEWS: Regeneron says its antibody cocktail reduces the risk of contracting Covid by more than 80% for at least EIGHT MONTHS

  • Regeneron say its antibody cocktail REGEN-COV reduces the risk of contracting COVID-19 by 81.6% two to eight months after it is administered 
  • The drug was authorized last year as a treatment for the virus but has since been expanded so it can be used as a prophylactic  

Regeneron Pharmaceuticals Inc announced on Monday that its antibody cocktail can severely slash the risk of being infected with COVID-19 for up to eight months. 

The combo therapy, REGEN-COV, was approved in November 2020 for emergency use to treat people with mild-to-moderate COVID-19 cases in the U.S.

But the U.S. Food and Drug Administration (FDA) expanded authorization in July 2021 so the drug can also be used as a preventive treatment.

Late-stage trial data showed a single dose can lower the risk of contracting Covid by 81.6 percent between two and six-months after the cocktail is administered. 

Regeneron say its antibody cocktail REGEN-COV (above) reduces the risk of contracting COVID-19 by 81.6% two to eight months after it is administered 

‘Today’s new data demonstrate how a single dose of REGEN-COV can help protect people from COVID-19 for many months after administration,’ Dr Myron S. Cohen, who leads the monoclonal antibody efforts for the COVID Prevention Network sponsored by the National Institutes of Health, said in a statement.

‘These results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection, a result particularly important to those who do not respond to COVID-19 vaccines including people who are immunocompromised.’ 

The antibody cocktail, REGEN-COV, is a combination of two drugs: casirivimab and imdevimab.

Both are monoclonal antibodies – laboratory-made proteins that mimic the immune system – that target the the spike protein, which the virus uses to enter and infect cells.

These cocktails deliver virus-fighting antibodies into the body unlike traditional vaccines in which the receiver’s immune system is activated to develop its own antibodies.

According to trial data released in April, REGEN-COV reduced the risk of symptomatic infections by 72 percent in the first week, and 93 percent after that.

This led to the FDA expanding the drug’s EUA as a prophylactic.

This can help reduce the risk of infection for patients who are at high risk of exposure in settings such as nursing homes or prisons, as well as for those with weakened immune systems including HIV and organ transplant patients. 

This is a breaking news story and will be updated.

For all the latest health News Click Here 

Read original article here

Denial of responsibility! TechAI is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.